Validation of Lysyl Oxidase As a Prognostic Marker for Metastasis and Survival in Head and Neck Squamous Cell Carcinoma: Radiation Therapy Oncology Group Trial 90-03
Quynh‐Thu Le(Stanford Medicine), K. Kian Ang(Moffitt Cancer Center)
Cited by 87
Related Papers
Galectin-1–driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance
|Journal of Clinical Investigation|2019|174
<i>NFE2L2</i> Mutations Enhance Radioresistance in Head and Neck Cancer by Modulating Intratumoral Myeloid Cells
|Cancer Research|2023|56